Maple-syrup-urine disease (Q40000): Difference between revisions

From determinar.ia.br - Determine suas informações
Created a new Item
 
Changed an Item
 
(7 intermediate revisions by the same user not shown)
description / pt-brdescription / pt-br
 
A doença da urina do xarope de ácer (ou bordo) é um distúrbio do metabolismo dos aminoácidos de cadeia ramificada. Quatro formas são descritas. A forma clássica de início precoce se manifesta após o nascimento por letargia, má alimentação e sinais neurológicos de intoxicação. O curso clínico sem tratamento é caracterizado pelo aprofundamento do coma com urina com odor de xarope de bordo . A forma subaguda se manifesta posteriormente com encefalopatia, deficiência mental, hipotonia importante, opistótono e atrofia cerebral com desfecho grave. A forma intermitente pode se manifestar em qualquer idade e se apresenta com coma cetoacidótico repetido. A forma responsiva à tiamina é uma forma muito rara caracterizada pela melhora do perfil bioquímico com a terapia com tiamina.
description / endescription / en
 
Maple syrup urine disease (MSUD) is a disorder of branched-chain amino acids metabolism. Four forms are described. The early onset classic form manifests after birth by lethargy, poor feeding and neurological signs of intoxication. Clinical course without treatment is characterised by deepening coma with maple syrup odour of urine. Subacute MSUD manifests later with encephalopathy, mental disability, major hypotonia, opisthotonus and cerebral atrophy with severe outcome. The intermittent form of MSUD may manifest at any age and presents with repeated ketoacidotic coma. Thiamine-responsive MSUD is a very rare form characterised by improvement of the biochemical profile with thiamine therapy.
Property / Canonical URI
 
Property / Canonical URI: https://id.who.int/icd/entity/1623706568 / rank
 
Normal rank
Property / CURIE
 
CID11:5C50.D0
Property / CURIE: CID11:5C50.D0 / rank
 
Normal rank
Property / Canary Token
 
dki-india-5C50.D0
Property / Canary Token: dki-india-5C50.D0 / rank
 
Normal rank
Property / Verification Status
 
Concluído
Property / Verification Status: Concluído / rank
 
Normal rank
Property / Knowledge Architect
 
Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank
 
Normal rank
Property / Collection date
 
13 August 2026
Timestamp+2026-08-13T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / Collection date: 13 August 2026 / rank
 
Normal rank
Property / Linked ICD 10
 
Property / Linked ICD 10: E71.0 / rank
 
Normal rank

Latest revision as of 05:38, 13 August 2026

Maple syrup urine disease (MSUD) is a disorder of branched-chain amino acids metabolism. Four forms are described. The early onset classic form manifests after birth by lethargy, poor feeding and neurological signs of intoxication. Clinical course without treatment is characterised by deepening coma with maple syrup odour of urine. Subacute MSUD manifests later with encephalopathy, mental disability, major hypotonia, opisthotonus and cerebral atrophy with severe outcome. The intermittent form of MSUD may manifest at any age and presents with repeated ketoacidotic coma. Thiamine-responsive MSUD is a very rare form characterised by improvement of the biochemical profile with thiamine therapy.
Language Label Description Also known as
default for all languages
5C50.D0
    English
    Maple-syrup-urine disease
    Maple syrup urine disease (MSUD) is a disorder of branched-chain amino acids metabolism. Four forms are described. The early onset classic form manifests after birth by lethargy, poor feeding and neurological signs of intoxication. Clinical course without treatment is characterised by deepening coma with maple syrup odour of urine. Subacute MSUD manifests later with encephalopathy, mental disability, major hypotonia, opisthotonus and cerebral atrophy with severe outcome. The intermittent form of MSUD may manifest at any age and presents with repeated ketoacidotic coma. Thiamine-responsive MSUD is a very rare form characterised by improvement of the biochemical profile with thiamine therapy.

      Statements

      CID11:5C50.D0
      0 references
      dki-india-5C50.D0
      0 references
      Concluído
      0 references
      13 August 2026
      0 references
      0 references